We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Carbapenem-Resistant Enterobacteriaceae Pose Triple Threat

By LabMedica International staff writers
Posted on 20 Mar 2013
Carbapenem-resistant Enterobacteriaceae (CRE) are an increasing and deadly threat in healthcare facilities in the United States of America. More...


Enterobacteriaceae are a large family of gram-negative bacilli that normally live in the human gastrointestinal tract, and are a common cause of both community- and healthcare-acquired infections.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has now issued an early warning, while the resistant infection is so far limited to inpatient facilities. Although resistance to broad-spectrum antibiotics has been seen for several decades, resistance to the carbapenem antimicrobial class is recent and appears to be spreading. During the first six months of 2012, among the 3,918 US acute-care hospitals performing surveillance for either catheter-associated urinary tract infections (CAUTI) or central-line-associated bloodstream infections (CLABSI) in any part of their hospital, 181 (4.6%) reported one or more infections with CRE, 145 in short-stay hospitals and 36 in long-term acute-care hospitals.

During the 5-month Emerging Infections Program (EIP) project pilots, 72 CRE were identified from 64 patients; 56 patients had 1 positive culture; 8 had 2. Fifty-nine came from the Atlanta metropolitan area, with 10 in the Minneapolis-St. Paul area and 3 from Portland, Oregon. There were 49 CRE identified as Klebsiella species, 14 as Enterobacter species and nine were Escherichia coli. The most common source was urine at 89%, with 10% in blood samples.

Thomas Frieden, MD, MPH, the CDC director, called CRE "nightmare bacteria" that post a "triple threat," because the organisms are resistant to nearly all antibiotics, they kill up to half of those infected, and they are capable of spreading their resistance to other bacteria. He advised that hospitals, nursing homes, and long-term care institutions adopt the recommendations issued previously in a CRE prevention toolkit.

Hospitals that have adopted the toolkit's recommendations have seen dramatic reductions in CRE infections. It advises measures such as requesting information about CRE-infected patients from laboratories; enforcing standard infection control and contact precautions; grouping CRE-infection inpatients together, using dedicated staff and equipment if possible; and prudent antimicrobial use. The report was published on March 8, 2013, in the journal Morbidity and Mortality Weekly Report.

Related Links:
US Centers for Disease Control and Prevention



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.